original contributions OAT 1/3 Intergenic SNP and Diuretics Response functional allele frequencies are low (<5%) in the OAT3 coding region. 19, 20 So far, only one study assessed the association of 22 SNPs in OAT1, OAT3, and OAT4 with the renal clearance of torsemide (a loop diuretic) in 95 healthy men; renal clearance of torsemide has been found to be associated with SNPs in OAT4 but in neither OAT1 nor OAT3. 21 OAT1 and OAT3 are localized in the human genome as a tightly linked gene pair. 22 Thus, intergenic variants between OAT1 and OAT3 might be potential candidates due to the presence of phylogenetic footprints in the intergenic region containing putative transcription factor-binding sites. Most SNPs in the OAT1 and OAT3 intergenic region are infrequent in Han Chinese, based on the HapMap Project, Han Chinese in Beijing (CHB) database (public releases up to January 2008). An intergenic SNP, rs10792367, is located at a position 6.3 kb from 5′-flanking region of OAT1 and 1.5 kb from 3′-flanking region of OAT3 (Figure 1) , with a minor allele frequency of 46.4% in the CHB population, and close to one of the reported phylo genetic footprints in the 5′-flanking region of OAT1. 22 Therefore, we hypothesized that SNP rs10792367 could be associated with adult hypertension or with the antihypertensive effects of hydrochlorothiazide (HCTZ). Our hypothesis was tested in two independent case-control populations, and in two clinical trials with chronic HCTZ treatment.
Methods
To validate the observed genetic association, we planned two independent populations for replication of the results of casecontrol studies, and conducted two clinical trials of chronic HCTZ treatment to detect the effect of SNP rs10792367 on BP response to HCTZ.
Two case-control hypertension studies.
A community-based approach was used in this study. Two independent samples were recruited from two different areas in China. Unrelated hypertensive patients and normotensive controls aged 40-75 years and of either sex were enrolled from the same communities. Patients were defined as hypertensive if they had systolic BP (SBP) and/ or diastolic BP (DBP) levels ≥140/90 mm Hg on three occasions within 2 months and if they were without any antihypertensive treatment, and/or if they were diagnosed as hypertensive in the past and were currently receiving anti hypertensive medications. Normotensive controls were defined as having SBP and/ or DBP levels <130/85 mm Hg without family history of hypertension. Subjects were excluded if they had evidence of renal disease or secondary hypertension. The first study population comprised of 820 hypertensive patients and 772 age-and sexmatched controls from Xinyang, Henan province. The second population comprised of 286 hypertensive patients and 316 controls from Rizhao, Shandong province, selected according to the same criteria as the first study.
Two clinical trials of the HCTZ treatment. Patients in two clinical trials of the HCTZ treatment were chosen from hypertensive patients in the two case-control studies. To avoid the confounding influence of previous therapy on the genetic effect, we only recruited untreated patients, including newly discovered patients or those having stopped antihypertensive therapy themselves (noncompliance) for at least 8 weeks before the study. The exclusion criteria were as follows: inability to continue antihypertensive treatment for at least 4 weeks; SBP >180 mm Hg and/ or DBP >110 mm Hg; inability to discontinue drugs that could antagonize the effect of HCTZ; allergy to HCTZ, stroke, coronary heart disease, diabetes mellitus as well as gout.
The first clinical trial recruited 542 hypertensive patients from the first case-control study to receive HCTZ treatment from March to May 2005. Details of the study protocol have been previously described. 23 Briefly, patients were treated with 25 mg of HCTZ daily (Changzhou Pharmaceuticals, Changzhou, China). The BP and serum potassium concentrations were measured after 2 and 4 weeks of treatment. Oral potassium supplements (20-40 mmol/l/day) were prescribed after 2 weeks if serum potassium was <3.5 mmol/l. At the end of the first 2 weeks, 311 patients continued with 25 mg of HCTZ per day, while the others received other kinds of antihypertensive drugs (n = 231) due to uncontrolled BP. The BP response to HCTZ was defined as the difference in the BP levels between post-treatment at 4 weeks and pretreatment.
The second trial enrolled 274 untreated patients in the second case-control study from June to September 2006, based on the same exclusion criteria. The study protocol was basically the same as the first clinical trial with some modifications. BP and adverse effect were recorded at the end of 2 and 4 weeks of HCTZ treatment (25 mg/day). Most patients continued with the treatment of HCTZ for 8 weeks (n = 245), unless the patient wished to withdraw from the trial or reported intolerable adverse effects or severe uncontrolled BP (>160/100). The BP responses were measured at the end of 2, 4, and 8 weeks of HCTZ treatment.
The protocols for all of the four studies were approved by the Ethic Committees of both the Fuwai Hospital and local collaborative hospitals, and adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from each individual enrolled and all of the subjects were reported to be of Han Chinese ethnicity.
Measurements. BP was measured by trained professionals with a standardized mercury sphygmomanometer and appropriate original contributions OAT 1/3 Intergenic SNP and Diuretics Response cuff sizes (regular adult, large, or thigh) in the subject's right arm. All participants were asked to avoid alcohol, smoking, coffee/tea, and exercise for at least 30 min before the BP measurement. The sitting BP measurement was taken three times: ≥30 s apart and after ≥5 min of rest; and an average of three readings was used as analyzed BP levels. The following demographic and vascular risk factors for each individual were determined: body mass index (BMI), waist-hip ratio, fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum creatinine. Smoking status and alcohol consumption were obtained by qualified health professionals using a standardized questionnaire. All patients underwent a standardized 12-lead electrocardiogram.
SNP selection and genotyping. The intergenic SNP rs10792367 was selected because of its location close to one of the reported phylogenetic footprints in the 5′-flanking region of OAT1 (ref. 22) and its higher minor allele frequency. There is no other reported SNP in linkage disequilibrium with rs10792367 within a distance of 39.3 kb, which spans the overall region of both genes (OAT1 and OAT3), including the intergenic region. This calculation was performed using the HapMap CHB SNP database and the pair-wise option of the Haploview version of the Tagger program when a minimum r 2 of 0.8 was chosen as a threshold. SNP rs10792367 was detected by standard PCR-restriction fragment length polymorphism analysis, gel electrophoresis, and ethidium bromide staining. All aspects of DNA source, preparation, and genotyping were controlled using the paradigms of blindness and randomization. The reproducibility of the genotyping was confirmed as 100% by bidirectional sequencing of 100 randomly selected samples. The sequences of primers used were: 5′-CAG TGC TGG GTA AGA ATG T-3′ and 5′-GTC TCG GTT CCT CAT CAG-3′. The resultant PCR products were digested with SacI (New England Biolabs, Ipswich, MA ).
Statistical analysis. Data are expressed as mean ± s.d. The quantitative variables were tested with Student's t-test or one-way analysis of variance. A χ 2 -test was applied to compare qualitative variables, allele/genotype frequencies (under recessive and dominant models), and the Hardy-Weinberg equilibrium. An Armitage's trend test was used to compare genotype frequencies between cases and controls under an additive model. The association of rs10792367 with hypertension was analyzed by a multivariate logistic regression model, adjusted for age, sex, BMI, serum lipids, and fasting blood glucose (in the first and second study) and geographic location (in the combined study), and expressed as an odds ratio and 95% confidence interval. A linear regression model was used to assess the association of rs10792367 with BP responses, with adjustment for pretreatment BP, age, sex, BMI, serum lipids, and fasting blood glucose. A two-tailed P value of <0.05 was considered statistically significant. The first study had >85% statistical power to detect an association (at P = 0.05) with odds ratio of ≥1.25 for alleles at 40-46% frequency assuming an additive model, and the combined study improved the statistical power to 96% for detecting an association with the same assumed parameters, reducing the probability of a false-negative result. Statistical analyses were carried out by SPSS 13.0. results association between rs10792367 and hypertension Table 1 summarizes the clinical characteristics of hypertensive patients and controls in the two case-control studies. As expected, hypertensive patients had significantly higher SBP and DBP levels, as well as serum lipids, than did normotensive controls (all P < 0.05).
The frequencies of rs10792367 genotypes in the two independent populations conformed to the Hardy-Weinberg equilibrium in both hypertensive patients and normotensive controls. As shown in Table 2 , we tested for the association of rs10792367 with hypertension under additive, dominant, and recessive models; however, no association was found, even after adjusting for age, sex, BMI, serum lipids, and fasting blood glucose, in either study. After combining the two studies and adjusting for the geographic location and other confounding factors, no association was found between rs10792367 and hypertension as well. The associations between rs10792367 genotypes and conventional risk factors, including age, sex, BMI, and dyslipidemia, were also examined in hypertensive patients and controls; no effect of rs10792367 on conventional risk factors was found in either population.
association between rs10792367 and BP responses to hctZ
In the first clinical trial, 542 patients received 2 weeks of HCTZ treatment while 311 patients continued taking HCTZ for 4 weeks. The BP responses to HCTZ by genotypes of rs10792367 are shown in Table 3 . Linear regression analysis showed that rs10792367 was associated with BP responses to 4 weeks of HCTZ treatment, but not with 2 weeks of treatment, after adjusting for covariates, including pretreatment BP, age, sex, BMI, serum lipids, and fasting blood glucose ( Table 3) . The polymorphism accounted for 2% of the between-individual variation in BP response to 4 weeks of HCTZ treatment, and together with other covariates, accounted for 37.9% of the between-individual variation in the SBP response and 36.2% of the between-individual variation in the DBP response. The BP reduction in C allele carriers was significantly lower than that in GG carriers. The adjusted mean differences were 4.8 mm Hg for SBP (P = 0.006) and 2.2 mm Hg for DBP (P = 0.015; Figure 2a) .
BP responses were recorded at the end of 2, 4, and 8 weeks of HCTZ treatment in the second clinical trial. No association was found between rs10792367 and BP response to 2 weeks of treatment. However, the analysis confirmed the association of rs10792367 with the SBP response to 4 and 8 weeks of treatment with HCTZ, even after adjusting for covariates ( Table 4) . The model including covariant and genotypes accounted for 25.3% of the between-individual variation in the SBP response to 4 weeks and 31.4% of that to 8 weeks of treatment with HCTZ. However, intergenic SNP rs10792367 was not associated with DBP response after either 4 or 8 weeks of HCTZ treatment. The adjusted differences between C original contributions OAT 1/3 Intergenic SNP and Diuretics Response allele and GG carriers were 3.5 mm Hg (P = 0.04) in SBP and 1 mm Hg (P = 0.09) in DBP at the end of 4 weeks. As shown in Figure 2b , after 8 weeks of treatment, the adjusted differences between C allele and GG carriers remained significant for SBP (6.1 mm Hg, P = 0.003), but did not reach statistical significance for DBP response (2.3 mm Hg, P = 0.08).
dIscussIon
This study revealed that the intergenic SNP rs10792367 between OAT1 and OAT3 genes was significantly associated with BP response to chronic HCTZ treatment in hypertensive patients, mainly driven by the association of the C allele with SBP reduction. Interestingly, the association between rs10792367 and hypertension risk was not detected in either of two independent studies or in the combined study, suggesting that the contribution of rs10792367 to the prediction of SBP response is independent of BP variation. As the human OAT1 and OAT3 gene pair is involved in the transport of thiazide diuretics and BP regulation, our results not only support the influence of OAT1 and OAT3 genetic variants on antihypertensive effects of original contributions OAT 1/3 Intergenic SNP and Diuretics Response thiazide diuretics, but also provide some insights into the effect of the OAT genes on BP regulation. Recent molecular and genetic discoveries have improved our understanding of transporter-mediated processes for a wide variety of metabolites and xenobiotics. 24, 25 The physiological role of OAT1 and OAT3 has been demonstrated in many studies. [9] [10] [11] [12] Both OAT transporters are indirectly coupled to the sodium gradient maintained by Na, K-ATPase, through sodium/dicarboxylate cotransport, to drive the uphill basolateral step in renal organic anion secretion. 7 Similarly, OAT1 and OAT3 contribute to normal renal secretion of loop and thiazide diuretics, and a lack of either one is not fully compensated for by the other. 12 A series of experiments have ascertained that OAT1 and OAT3 are under the regulation of several transcription factors, as well as epigenetic influences, such as DNA methylation. 22, [26] [27] [28] [29] Binding sites for related transcription factors have been identified in the noncoding regions and promoter regions of OAT1 and OAT3. 22, [26] [27] [28] Some phylogenetic footprints containing putative transcription factor-binding sites have also been identified in the intergenic region between human OAT1 and OAT3. 22 Noncoding polymorphisms near transcriptional regulatory elements (including potential sex steroid response elements) might have an influence on the level of transcription of the OAT1 and OAT3 genes. 17 Although the research discussed above has prompted considerable interest in OAT pharmacogenomics, negative results are reported in most studies for associations of OAT1 and OAT3 polymorphisms with drug disposition and elimination, 14, 15, [19] [20] [21] as well as apparent functional effects. 16, 18 Several functional SNPs in the coding region of OAT3 have low allele frequencies. 19, 20 To the best of our knowledge, our study is the first to report the predictive value of OAT1 and OAT3 polymorphisms on the antihypertensive effect of thiazide diuretics, facilitating expected OAT pharmacogenomics.
The mechanism underlying the predictive value of intergenic SNP rs10792367 for BP responses to HCTZ remains unknown. The most plausible explanation is that rs10792367 is in linkage disequilibrium with an as yet undiscovered functional mutation in the regulatory region of OAT1 and/or OAT3. However, recent research has highlighted the regulatory function of noncoding genome regions. 30, 31 Intergenic regions, as well as intronic regions, are now known to harbor multiple regulatory elements that control the fine-tuned temporal and spatial transcription of genes. 32, 33 Some disease-linked intergenic SNPs contribute to clinical manifestations by driving molecular and biological antagonisms of intergenic SNP-containing transregulatory RNAs. 34 Therefore, another possible explanation is that rs10792367 is functional, and the rs10792367 C allele is associated with downregulation of OAT1 and/or OAT3, thereby causing between-individual variation in BP response to HCTZ. The functional effect of rs10792367 on OAT1 and/ or OAT3 expression needs to be investigated in the future. Our 35, 36 will provide useful information for optimizing personalized medicine, and suggest a novel concept regarding the contribution of intergenic polymorphisms to variability in drug response. The influence of OAT1 and OAT3 on BP regulation remains inconsistent. A potential role of Oat3 in BP regulation has been reported in mice, 13 but BP seems to be unaffected in Oat1 knockout mice. 11 Our study did not find an association between intergenic rs10792367 and increased susceptibility to hypertension. However, this negative result does not exclude the possibility that variations in the OAT3 gene might increase the risk of hypertension. Furthermore, it is well reported and documented in the literature that a gene polymorphism associated with BP response might not predict hypertension susceptibility. 36, 37 This discrepancy could also reflect the complex roles of OAT1 and/or OAT3 in BP regulation and drug response of thiazide diuretics. The pairing of OAT1 and OAT3 also suggests the possibility of co-regulation of the genes; 22 therefore, it is possible that OAT1 polymorphisms could affect expression of OAT3, and vice versa. 17 Our community-based approach minimized the influences of various lifestyles and environments. The replication of our findings in two independent populations provided quality control for avoiding the potential false-positive associations in our study. The combined study improved the power of the test, reducing the probability of a false-negative result for the association between polymorphism and hypertension. However, the study still has several limitations. First, it would be better to investigate all polymorphisms located in the whole region spanning the OAT1/OAT3 gene pair for genetic associations with hypertension and drug response. However, on the basis of previous negative results, our study provides specific information for the OAT1/OAT3 gene pair that is different from studies based on anonymous tag SNPs in candidate genes. Recently, many of the loci uncovered by genome-wide association studies fall in intergenic regions, 38 which has encouraged more research to uncover these elements. Second, the regulatory function of intergenic SNP rs10792367 is not elucidated in our study because uncovering the functions of elements in noncoding regions, and how they relate to regulatory networks and pathways underlying clinical manifestations remains a challenge.
In conclusion, this study found a significant pharmocogenomic association of an intergenic polymorphism, rs10792367, between OAT1 and OAT3 genes, with SBP response to chronic HCTZ treatment in hypertensive patients, and provided preliminary information for the negative association of OAT1 and OAT3 related polymorphisms with hypertension risk. Future studies should investigate the effect of genetic variants in both OAT1 and OAT3 genes on BP variations and antihypertensive effects. 
